2. Introduction
Respiratory failure secondary to surfactant
deficiency is a major cause of morbidity and
mortality in preterm infants.
RCTs confirm that
-reduces mortality,
-decrease pulmonary air leak
-lowers the risk of CLD
-reduces death at 28 days of age
8. Dosing
phospholipid content:100mg/kg(larger dose
have good acute response and longer half life)
Decision of Repeat doses??
FIO2 > 0.3 No radiological
improvement(lun
g expansion)
MAP >7 cm of
H2O(still on MV)
11. PROPHYLACTIC VERSUS
RESCUE
SURFACTANT
The meta-analysis of studies conducted before
routine application of CPAP demonstrated a
lower mortality rate and a decrease in the risk
of air leak in preterm infants receiving.
12. Animal derived vs Synthetic
Both animal-derived and newer synthetic
surfactants with SP-B–like activity decrease
acute respiratory morbidity and mortality in
preterm infants with RDS (LOE 1).
Animal derived surfactant are more desirable
despite incidence if IVH(grade 3 & 4
evidence).
13. Expected Complication of
therapy
Pulmonary Hemorrhage and edema
Apnea
Bradycardia
Blocked ETT
Air leaks
Possible infection
ICH
PDA
Hypothermia
14. AN steroids and Surfactant
Synergistic
Reduce mortality & morbidity
Reduce IVH
Reduce air leaks
15. In Indian scenario what we
see…..
Expensive
Choice of surfactant depends upon
economical condition of parents and
availability.
Hesitancy of about spending upon female
child.